Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Ingresos totales | ₹67.2B | ₹55.1B | ₹50.0B | ₹60.1B | — |
| Beneficio bruto | ₹39.6B | ₹29.7B | ₹25.0B | ₹31.7B | — |
| Ingresos operativos (EBIT) | ₹13.1B | ₹6.3B | ₹3.9B | ₹12.9B | — |
| Ingresos netos | ₹8.9B | ₹3.6B | ₹1.6B | ₹7.9B | — |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de LAURUSLABS. /companies/us/LAURUSLABS
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms